Benefits include better discrimination between risk levels. (HealthDay News) — Patient-centered pathology reports (PCPR) help patients to understand prostate cancer results better than current ...

This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this ...

symptoms receiving pharmacologic therapy for benign prostatic hyperplasia (BPH). Gemtesa, a β 3 adrenergic receptor agonist, dosed once daily (75 mg), has been approved for men with OAB symptoms ...

No such diagnosis has been announced. Netanyahu underwent prostate removal surgery after he was diagnosed with an infection stemming from a benign prostate enlargement, according to reputable news ...

“Women not only tend to present with more aggressive disease, but they also have a higher probability of having what we call variant histology, so non-urothelial carcinoma,” says Ava Saidian, MD. In ...

High-grade prostatic intraepithelial neoplasia (HGPIN ... and atypical adenomatous hyperplasia or adenosis), but the data for these premalignant diseases are much less convincing than those ...

The FDA approved vibegron (Gemtesa) to treat men with overactive bladder symptoms who are receiving pharmacological therapy for benign prostatic hyperplasia, Sumitomo Pharma said. Sequana Medical ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...